Evidence map›Paper›PMID 38330416›Full record

ReviewJournal of clinical neurology (Seoul, Korea)2024

New Directions in Infection-Associated Ischemic Stroke.

Jin-Man Jung, András Gruber, Peter Heseltine, Kumar Rajamani, Sebastián F Ameriso, Mark J Fisher

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of clinical neurology (Seoul, Korea), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Stroke, infections, and New Mechanisms: a Narrative Review.Current neurology and neuroscience reports · 2025
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 6 institutions in 4 countries.

Jin-Man JungDepartment of Neurology, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea; Korea University Zebrafish, Translational Medical Research Center, Ansan, Korea.ORCID https://orcid.org/0000-0003-0557-6431
András GruberAronora, Inc., Portland, OR, USA.ORCID https://orcid.org/0000-0001-6212-2247
Peter HeseltineDivision of Infectious Diseases, Department of Medicine, University of California, Irvine, Irvine, CA, USA.ORCID https://orcid.org/0000-0001-6172-2216
Kumar RajamaniDepartment of Neurology, Wayne State University-Detroit Medical Center, Detroit, MI, USA.
Sebastián F AmerisoDivision of Vascular Neurology, Department of Neurology, Fleni, Autonomous City of Buenos Aires, Argentina.ORCID https://orcid.org/0000-0001-8933-0847
Mark J FisherDepartment of Neurology, University of California Irvine Medical Center, Orange, CA, USA. mfisher@hs.uci.edu.ORCID https://orcid.org/0000-0001-9802-8826
Aronora (United States) · USFundación para la Lucha contra las Enfermedades Neurológicas de la Infancia · ARKorea University Medical Center · KRUniversity of California, Irvine · USUniversity of California, Irvine Medical Center · USWayne State University · US

Funding

National Research Foundation of Korea NRF-2020R1C1C1009294
6 · The paper itself

Abstract

The relationship between infections and stroke has not been fully characterized, probably delaying the development of specific treatments. This narrative review addresses mechanisms of stroke linked to infections, including hypercoagulability, endothelial dysfunction, vasculitis, and impaired thrombolysis. SARS-CoV-2, the virus that causes COVID-19, may promote the development of stroke, which may represent its most severe neurological complication. The development of specific therapies for infection-associated stroke remains a profound challenge. Perhaps the most important remaining issue is the distinction between infections that trigger a stroke versus infections that are truly incidental. This distinction likely requires the establishment of appropriate biomarkers, candidates of which are elevated levels of fibrin D-dimer and anticardiolipin/antiphospholipid antibodies. These candidate biomarkers might have potential use in identifying pathogenic infections preceding stroke, which is a precursor to establishing specific therapies for this syndrome.

Indexed as

anticardiolipin/antiphospholipid antibodiesfibrin D-dimerinfectionsstrokethrombosis

Identifiers

PMID38330416
PMCPMC10921058
OpenAlexW4392394271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.